Navigation Links
Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors
Date:4/15/2008

GLASGOW, Scotland, April 15 /PRNewswire/ -- Excalibur, the new international investment house launched by Sir Christopher Evans, today (Tuesday) welcomed the sale of PIramed to Roche.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 )

The sale of PIramed to Roche for $185 million means a 'very substantial cash return' to investors in Merlin III, the investment fund created by Sir Christopher five years ago.

Merlin Biosciences were co-founding investors in PIramed at the outset in 2003 with JP Morgan. Merlin, with the founders of the company, also selected the CEO, the management team, built the board of directors and continued to provide ongoing funding and strategic advice to the company.

Sir Christopher Evans said: "The sale is terrific news for everyone who has been associated with PIramed since the early days. It is complete vindication of the founders' vision and also the flawless execution of a scientific, management and investment plan that Merlin and JP Morgan stuck to from the outset. We are delighted to have been involved from day one and at Excalibur we are pleased to be delivering to investors in our Merlin Fund III such a substantial return on their investment."

Notes to Editors:

Excalibur has been founded by Professor Sir Christopher Evans and is a major new development of the original Merlin Biosciences business. Merchant Ventures, a specialist financial services group, was acquired to create Excalibur.

Excalibur is following the successful investment strategy of Merlin's Fund III which has focused more broadly on healthcare and medical science investments and is already delivering significant returns to investors with five more years to run.

The three existing Merlin investment funds operate under their original titles within the Excalibur group.

Key investors and stakeholders in Excalibur besides Sir Chris include Sir Tom Hunter's West Coast Capital, Professor Jeremy Stone, chairman of Merchant Ventures, and Lloyds TSB.

Further information:

Ramsay Smith,

Media House International.

Tel +44(0)207-397-8460/+44(0)7788-414856.

Email:ramsay@mediahouse.co.uk


'/>"/>
SOURCE Excalibur
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
2. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
3. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
4. Clinimetrics Celebrates 20th Anniversary in Contract Research Business
5. Guava Technologies Celebrates Tenth Anniversary
6. New Enterprise Forum Celebrates 22nd Anniversary, Presents Annual Entrepreneur Awards to Randal Charlton & Others
7. Winnick Family Clinical Research Center Celebrates 6th Anniversary
8. Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations
9. HCM Announces Substantial Growth in 2007
10. Cystic Fibrosis Trial In Children Returns Positive Data
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... BC, Canada (PRWEB) , ... July 20, 2017 , ... ... today announced the winning recipients of the 2017 IAC Awards at the 22nd World ... awards, the committee also named four faculty to receive the Distinguished Fellowship Awards. , ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... on digital pathology and artificial intelligence Tuesday, July 25, during the Association of ... from Johns Hopkins Medicine. , Baras, Associate Director of Pathology Informatics, will ...
(Date:7/20/2017)... ... July 20, 2017 , ... Crucial Data Solutions (CDS) ... study participants truly unified. TrialKit, a native mobile app, empowers investigators and clinicians ... studies entirely on mobile devices. With TrialKit, clinical researchers can utilize Core Motion ...
(Date:7/18/2017)... Switzerland (PRWEB) , ... July 18, 2017 , ... ... R&D, today announced that Merck, a leading science and technology company, has implemented ... innovative therapeutics for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
Breaking Biology News(10 mins):